FREEDOM2 Trial Shows Fedratinib’s Efficacy and Safety in Myelofibrosis
The FREEDOM2 study demonstrates that fedratinib is an effective second-line treatment for myelofibrosis after ruxolitinib failure or intolerance.
Read More
Choosing the Right JAK Inhibitor for Effective Myelofibrosis Treatment
In an interview, Prithviraj Bose, MD, discussed the multiple JAK inhibitors available for the treatment of patients with myeloproliferative neoplasms.
Exploring Advancements in Higher-Risk MDS
Despite recent setbacks in clinical trials, there is still hope for improving treatments for high-risk myelodysplastic syndromes.
Ruxolitinib Stands Out Among JAK2 Inhibitors for Myelofibrosis
Experts review the case of a 68-year-old woman diagnosed with primary myelofibrosis.
Phase 3 Trial of Bomedemstat in Essential Thrombocythemia Begins Enrollment
The phase 3 Shorespan-007 trial will compare bomedemstat with hydroxyurea in patients with treatment-naive essential thrombocythemia.
Tebapivat Scores FDA Orphan Drug Designation in MDS-Associated Anemia
Tebapivat, a novel pyruvate kinase activator, is being investigated for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.